ibrutinib,rituximab
abbvie,janssen
[' ibru']
adding ibrutinib to standard chemoimmunotherapy induction followed by asct &amp; 2 years of maintenance ibrutinib can significantly improve outcomes in comparison with standard chemoimmunotherapy induction and asct alone for younger patients with #mcl. #ash22 
Oncology news and insights from leading researchers and cancer centers.